CYCS and lung carcinoma: In lung cancer, PRRX1 knockdown inhibits the expression of Caspase 3, caspase 9, Apaf-1, and cytochrome C, leading to enhanced anti-apoptotic capacity and resistance to cisplatin in lung cancer cells41.